Influence of SLCO1B3 gene polymorphism on the pharmacokinetics of digoxin in terminal renal failure

Drug Metabolism and Pharmacokinetics

Volumn 23, Issue 6, 2008, Pages 406-411

  Tsujimoto, Masayuki ^a   Dan, Yukihiko ^b   Hirata, Sumio ^c   Ohtani, Hisakazu ^d   Sawada, Yasufumi ^d  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c KUMAMOTO UNIVERSITY   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

Digoxin; Genetic polymorphism; Non renal clearance; Organic anion transporting polypeptide (OATP) 1B3; SLC transporters; Terminal renal failure

Indexed keywords

DIGOXIN; GUANOSINE; ORGANIC ANION TRANSPORTER; PROTEIN SLCO1B3; THYMINE; UNCLASSIFIED DRUG; VERAPAMIL;

ALLELE; ARTICLE; CLINICAL ARTICLE; DNA POLYMORPHISM; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; GENE DELETION; GENE INSERTION; GENE LINKAGE DISEQUILIBRIUM; GENETIC VARIABILITY; GENOTYPE; HEMODIALYSIS PATIENT; HOMOZYGOSITY; HUMAN; KIDNEY FAILURE; MALE; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 67649361952     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.23.406     Document Type: Article

References (20)

1. Hagenbuch, B. and Meier, P. J.: The superfamily of organic anion transporting polypeptides. Biochim. Biophys. Acta., 1609: 1-18 (2003).
2. Smith, N. F., Marsh, S., Scott-Horton, T. J., Hamada, A., Mielke, S., Mross, K., Figg, W. D., Verweij, J., McLeod, H. L. and Sparreboom, A.: Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. Clin. Pharmacol. Ther., 81: 76-82 (2007).
3. Tanaka, H., Ueno, K., Matsumoto, K., Takada, M., Katayama, Y. and Shibakawa, M.: Effect of P-glycoprotein on pharmacokinetics of digoxin. Jpn. J. Ther. Drug Monit., 19: 149-150 (2002).
4. Doherty, J. E., de Soyza, N., Kane, J. J., Bissett, J. K. and Murphy, M. L.: Clinical pharmacokinetics of digitalis glycosides. Prog. Cardiovasc. Dis., 21: 141-158 (1978).
5. Pieringer, H. and Biesenbach, G.: Hemodialysis in patients older than 65 years with end-stage renal failure: Comparison of outcome in patients with and without diabetes. Z. Gerontol. Geriatr., 41: 139-145 (2008).
6. Salphati, L. and Benet, L. Z.: Metabolism of digoxin and digoxigenin digitoxosides in rat liver microsomes: involvement of cytochrome P4503A. Xenobiotica, 29: 171-185 (1999).
7. Kullak-Ublick, G. A., Ismair, M. G., Stieger, B., Landmann, L., Huber, R., Pizzagalli, F., Fattinger, K., Meier, P. J. and Hagenbuch, B.: Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology, 120: 525-533 (2001).
8. Ismair, M. G., Stieger, B., Cattori, V., Hagenbuch, B., Fried, M., Meier, P. J. and Kullak-Ublick, G. A.: Hepatic uptake of cholecystokinin octapeptide by organic anion-transporting poly-peptides OATP4 and OATP8 of rat and human liver. Gastroenterology, 121: 1185-1190 (2001).
9. Tsuji, A.: Transporter-mediated drug interactions. Drug Metab. Pharmacokinet., 17: 253-274 (2002).
10. Mizuno, N. and Sugiyama, Y.: Drug transporters: their role and importance in the selection and development of new drugs. Drug Metab. Pharmacokinet., 17: 93-108 (2002).
11. Cui, Y., Konig, J., Nies, A. T., Pfannschmidt, M., Hergt, M., Franke, W. W., Alt, W., Moll, R. and Keppler, D.: Detection of the human organic anion transporters SLC21A6 (OATP2) and SLC21A8 (OATP8) in liver and hepatocellular carcinoma. Lab. Invest., 83: 527-538 (2003).
12. Shitara, Y., Itoh, T., Sato, H., Li, A. P. and Sugiyama, Y.: Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporinA. J. Pharmacol. Exp. Ther., 304: 610-616 (2003).
13. Nishizato, Y., Ieiri, I., Suzuki, H., Kimura, M., Kawabata, K., Hirota, T., Takane, H., Irie, S., Kusuhara, H., Urasaki, Y., Urae, A., Higuchi, S., Otsubo, K. and Sugiyama, Y.: Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin. Pharmacol. Ther., 73: 554-565 (2003).
14. Pasanen, M. K., Neuvonen, M., Neuvonen, P.J. and Niemi, M.: SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet. Genomics., 16: 873-879 (2006).
15. Zhang,W., He, Y. J., Han, C. T., Liu, Z. Q., Li, Q., Fan, L., Tan, Z. R., Zhang, W. X., Yu, B. N.,Wang, D., Hu, D. L. and Zhou, H. H.: Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide. Br. J. Clin. Pharmacol., 62: 567-572 (2006).
16. Niemi, M., Backman, J. T., Kajosaari, L. I., Leathart, J. B., Neuvonen, M., Daly, A. K., Eichelbaum, M., Kivisto, K. T. and Neuvonen, P. J.: Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin. Pharmacol. Ther., 77: 468-478 (2005).
17. Tsujimoto, M., Hirata, S., Dan, Y., Ohtani, H. and Sawada, Y.: Polymorphisms and linkage disequilibrium of the OATP8 (OATP1B3) gene in Japanese subjects. Drug Metab. Pharmacokinet., 21: 165-169 (2006).
18. Verschraagen, M., Koks, C. H., Schellens, J. H. and Beijnen, J. H.: P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil. Pharmacol. Res., 40: 301-306 (1999).
19. Letschert, K., Keppler, D. and Konig, J.: Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8). Pharmacogenetics, 14: 441-452 (2004).
20. Gault, M. H., Sugden, D., Maloney, C., Ahmed, M. and Tweeddale, M.: Biotransformation and elimination of digoxin with normal and minimal renal function. Clin. Pharmacol. Ther., 25: 499-513 (1979).